

Ghana Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Ghana

2. Grant number(s): 15-GHA-08h-Y; 1518-GHA-25c-X

3. Date of Decision Letter: 21 December 2017

4. Date of the Partnership Framework Agreement: 11 July 2014

5. Programme title: NVS, IPV routine

6. Vaccine type: Inactivated Polio Vaccine (IPV)

7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID

8. Programme duration²: 2015 - 2018

 Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement, if applicable)

Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.

	2015-2017	2018	Total ³
Routine Programme (US\$)	54,268 ⁴	US\$1,047,500	US\$1,101,768
Catch-up vaccination (US\$)	0	0	0
Total budget	54,2685	US\$1,047,500	US\$1,101,768

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2018.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.



10. Vaccine introduction grant: US\$ 646,000 was disbursed on 10 March 2015

11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁶

2015-2017	2018
	1,262,900
54,268	US\$1,047,500

12. Procurement agency: UNICEF.

13. Self-procurement: Not applicable

14. Co-financing obligations:

Gavi's usual co-financing requirements do not apply to IPV. However, Ghana is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for catch-up campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of	May
vaccines, Country shall submit the following	
information in May each year: number of children	
to be vaccinated, vaccine stock levels including	
buffer stock, wastage rates, any proposed	
changes in presentation or minimum co-financing	
levels and vaccines received.	
In accordance with applicable Gavi processes,	To be agreed with Secretariat
Country shall report on programmatic and	
financial performance.	

17. Financial clarifications: Not applicable

18. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Ghana envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Ghana.

_

⁶ This is the amount that Gavi has approved.



The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

Signed by, On behalf of Gavi

That I . Thath

Hind Khatib-Othman Managing Director, Country Programmes 21 December 2017